Form 4: Compass Pathways Director George Jay Goldsmith Reports Share Sales
SEC Form 4
George Jay Goldsmith, a director at Compass Pathways, reported the sale of ordinary shares on April 16 and 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- George Jay Goldsmith, a director of Compass Pathways plc, reported the sale of ordinary shares on April 16 and 17, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.
- On April 16, 2024, 23,881 shares were sold at a weighted average price of $8.5289, with individual prices ranging from $8.17 to $8.83.
- On the same day, 23,880 shares held indirectly by his spouse were sold at the same weighted average price.
- On April 17, 2024, 10,850 shares were sold at a weighted average price of $8.7841, with individual prices ranging from $8.70 to $8.88.
- On the same day, 10,850 shares held indirectly by his spouse were sold at the same weighted average price.
- Following these transactions, Mr. Goldsmith directly owns 3,975,673 shares and indirectly owns 3,973,400 shares through his spouse, Dr. Ekaterina Malievskaia.
- Both Mr. Goldsmith and Dr. Malievskaia have disclaimed beneficial ownership of each other's shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports transactions under a pre-existing trading plan, without indicating any positive or negative outlook for the company.
Industry Context
Insider trading activity is always closely watched in the pharmaceutical industry, especially for companies like Compass Pathways that are developing novel therapies. These sales could be interpreted in various ways, but the existence of a pre-arranged trading plan mitigates concerns about opportunistic trading based on inside information.
Comparison to Industry Standards
- Comparing Goldsmith's transactions to those of insiders at similar biotech firms like MindMed or Atai Life Sciences reveals that such sales under 10b5-1 plans are common.
- For example, executives at MindMed have also utilized 10b5-1 plans to manage their stock holdings, as disclosed in their SEC filings.
- The scale of Goldsmith's sales is within the typical range for directors at companies of Compass Pathways' size and market capitalization.
Stakeholder Impact
- The sales could create short-term selling pressure on the stock.
- However, the existence of a pre-arranged trading plan should reassure investors that the sales are not based on negative insider information.
Key Dates
| Date | Description |
|---|---|
| 2023/08/23 | Date of adoption of Rule 10b5-1 trading plan by Mr. Goldsmith and Dr. Malievskaia |
| 2024/04/16 | Date of first reported transaction: sale of ordinary shares |
| 2024/04/17 | Date of second reported transaction: sale of ordinary shares |
| 2024/04/18 | Date of signature of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.